PCL (Polycaprolactone)

Material Also known as: Polycaprolactone

Quick Overview

PCL is a synthetic biodegradable polyester with exceptional flexibility, low melting point, and excellent blending capabilities. Primarily used in medical devices and specialty applications requiring biocompatibility and controlled biodegradation.

Related terms: Biodegradable PLA PHA

Overview

Polycaprolactone (PCL) is a synthetic biodegradable polyester distinguished by its exceptionally low melting point, high flexibility, and excellent compatibility with other polymers. While less well-known than PLA or PHA, PCL occupies a crucial niche in applications requiring biocompatibility, controlled degradation rates, and superior processing characteristics at low temperatures.

PCL’s unique properties make it invaluable for medical and pharmaceutical applications, where its biocompatibility, non-toxicity, and FDA approval enable uses ranging from absorbable sutures to controlled-release drug delivery systems. Additionally, PCL serves as an important compatibilizer and modifier in bioplastic blends, improving the properties of more brittle materials like PLA.

Chemical Structure and Production

Synthesis: PCL is produced through ring-opening polymerization of ε-caprolactone, a seven-membered cyclic ester:

  1. Polymerization: ε-caprolactone monomers undergo ring-opening polymerization using catalysts (typically stannous octoate or aluminum alkoxides)
  2. Molecular weight control: Polymerization conditions and catalyst ratios determine final molecular weight (10,000-100,000 Da)
  3. Purification: The polymer is purified to remove residual monomers and catalysts

Feedstock Sources: ε-caprolactone is traditionally produced from petroleum-based cyclohexanone. However, bio-based routes are emerging:

  • Fermentation of sugars to produce bio-based cyclohexanone
  • Conversion of bio-based adipic acid to caprolactone
  • Direct microbial production of caprolactone from renewable feedstocks

Currently, most commercial PCL is petroleum-derived, though bio-based PCL is entering the market.

Key Properties and Characteristics

Thermal Properties:

  • Extremely low melting point: 58-60°C (lowest among common bioplastics)
  • Glass transition temperature: -60°C
  • Processing temperature: 70-100°C
  • Heat deflection temperature: ~45°C

Mechanical Properties:

  • Tensile strength: 10-25 MPa (relatively low)
  • Elongation at break: 400-900% (highly flexible and elastic)
  • Low modulus: 200-400 MPa (soft, rubber-like behavior)
  • Excellent impact resistance
  • High toughness and tear resistance

Biodegradability: PCL biodegrades through enzymatic hydrolysis, but at slower rates than PLA or PHA:

  • Industrial composting: 6-12 months
  • Soil: 1-2 years
  • Marine environments: 6-24 months
  • Biomedical applications: Controlled degradation over 6-24 months depending on molecular weight

PCL’s slower degradation rate is actually advantageous for applications requiring extended service life before biodegradation.

Blending and Compatibility: PCL exhibits exceptional miscibility with numerous polymers:

  • Improves PLA flexibility and impact resistance when blended
  • Compatible with starch, cellulose, and natural polymers
  • Can be blended with conventional plastics (PVC, PE) to impart biodegradability
  • Serves as compatibilizer in immiscible polymer blends

Applications and Markets

Medical and Pharmaceutical: PCL’s primary market leverages its biocompatibility and FDA approval:

Absorbable Medical Devices:

  • Surgical sutures that degrade over time
  • Bone fixation screws and pins
  • Tissue engineering scaffolds
  • Cardiovascular stents and patches
  • Wound dressings and skin closure strips

Drug Delivery:

  • Controlled-release microspheres
  • Subcutaneous implants for hormone delivery
  • Biodegradable drug-eluting coatings
  • Long-acting injectable formulations

Tissue Engineering:

  • Scaffolds for bone and cartilage regeneration
  • Nerve guidance conduits
  • Vascular grafts
  • Cell culture substrates

3D Printing: PCL’s low melting point makes it ideal for:

  • Biomedical 3D printing (patient-specific implants)
  • Desktop 3D printers (lower temperature requirements)
  • Educational and prototyping applications
  • Custom medical devices

Packaging and Films:

  • Specialty flexible packaging
  • Biodegradable coatings for paper
  • Compostable bags (blended with starch or PLA)
  • Agricultural films

Adhesives and Sealants:

  • Hot-melt adhesives (low melting point advantage)
  • Biodegradable adhesives for paper and packaging
  • Moisture-cure adhesives

Polymer Modification:

  • Flexibility modifier for PLA and other rigid bioplastics
  • Impact modifier for brittle polymers
  • Compatibilizer in polymer blends

Advantages and Benefits

Biocompatibility: PCL’s excellent biocompatibility and FDA approval for medical use make it the gold standard for biodegradable medical devices. It has been used clinically for decades with extensive safety data.

Controlled Degradation: PCL’s slower, more predictable degradation rate compared to PLA enables applications requiring extended service life (6-24 months) before biodegradation.

Low Processing Temperature: The ability to process PCL at 70-100°C reduces energy consumption and enables applications incompatible with higher-temperature polymers (e.g., temperature-sensitive drug encapsulation).

Flexibility and Toughness: PCL’s rubber-like properties provide flexibility, impact resistance, and elongation that rigid bioplastics like PLA cannot match.

Blending Versatility: PCL’s excellent compatibility with other polymers makes it invaluable for creating custom bioplastic blends with tailored properties.

Challenges and Limitations

Low Mechanical Strength: PCL’s soft, flexible nature limits its use in applications requiring high tensile strength or rigidity.

Low Heat Resistance: With a melting point around 60°C, PCL cannot be used for hot food packaging, sterilization applications, or high-temperature environments.

Cost: PCL is expensive compared to commodity plastics and even other bioplastics, typically costing 3-5 times more than PLA. This limits its use to high-value applications like medical devices.

Limited Production Capacity: Global PCL production is relatively small (estimated 10,000-20,000 tonnes annually), creating supply constraints and maintaining high prices.

Slow Biodegradation: While advantageous for some applications, PCL’s slow degradation can be a limitation when rapid biodegradation is desired (e.g., single-use packaging).

Petroleum Dependence: Most commercial PCL is still produced from petroleum-based feedstocks, though bio-based alternatives are emerging.

Medical Device Growth: The global biodegradable medical device market is expanding rapidly, driven by:

  • Aging populations requiring more surgical interventions
  • Preference for absorbable devices eliminating removal surgeries
  • Advanced tissue engineering and regenerative medicine applications
  • Personalized medicine and 3D-printed patient-specific devices

PCL is positioned to capture significant share of this growing market.

Bio-based PCL Development: Multiple companies are developing fully bio-based PCL:

  • Fermentation routes to bio-caprolactone
  • Conversion of bio-based adipic acid
  • Engineered microorganisms producing caprolactone directly from sugars

Commercial bio-based PCL could reach the market by 2027-2028.

Advanced Blends: Innovation in PCL blends with PLA, PHA, and starch is creating materials with improved properties:

  • PLA/PCL blends combining PLA’s strength with PCL’s flexibility
  • PCL-modified starch for enhanced moisture resistance
  • PHA/PCL blends for marine-biodegradable applications

3D Printing Expansion: PCL’s low melting point positions it well for growth in biomedical 3D printing:

  • Patient-specific implants and prosthetics
  • Surgical guides and models
  • Tissue engineering scaffolds with precise geometries
  • Educational models for medical training

Regulatory Approvals: PCL’s extensive clinical history and safety profile facilitate regulatory approvals for new medical applications, accelerating commercialization of PCL-based innovations.

Market Projections: The PCL market is expected to grow 8-12% annually through 2030, reaching 40,000-50,000 tonnes production capacity. Growth will be driven primarily by medical and pharmaceutical applications, with secondary growth in specialty 3D printing and high-performance blends.

PCL represents a mature, clinically proven biodegradable polymer that excels in applications requiring biocompatibility, controlled degradation, and processing flexibility. While its higher cost and lower production volumes limit mass-market adoption, PCL’s unique properties ensure it will remain essential for medical devices, drug delivery systems, and specialized applications where performance and biocompatibility justify premium pricing.

Standards & Certifications

  • ASTM D6400
  • ISO 14855
  • FDA approved for medical use

Major Producers

  • Solvay (Capa)
  • Daicel Corporation
  • BASF
  • Perstorp
  • Corbion

Key Applications

  • Medical sutures
  • Drug delivery systems
  • 3D printing
  • Adhesives
  • Polymer blends
  • Biomedical implants